In the Dahlman Lab, we focus on the interface between nanotechology, molecular biology, and genomics. We design drug delivery vehicles that target RNA and other nucleic acids to cells in the body. We have delivered RNAs to endothelial cells, and have treated heart disease, cancer, inflammation, pulmonary hypertension, emphysema, and even vein graft disease. Because we can deliver RNAs to blood vessels at low doses, sometimes we decide to deliver multiple therapeutic RNAs to the same cell at once. These 'multigene therapies' have been used to treat heart disease and cancer. Why is this important? Most diseases are caused by combinations of genes, not a single gene. We also rationally design the nucleic acids we want to deliver. For example, we re-engineered the Cas9 sgRNA to turn on genes, instead of turning them off. This enabled us to easily turn on gene A and turn off gene B in the same cell.